Skip to main content

Human BLAME/SLAMF8 Biotinylated Antibody

R&D Systems, part of Bio-Techne | Catalog # BAF1907

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
BAF1907

Key Product Details

Validated by

Biological Validation

Species Reactivity

Human

Applications

Flow Cytometry, Western Blot

Label

Biotin

Antibody Source

Polyclonal Goat IgG

Product Specifications

Immunogen

Mouse myeloma cell line NS0-derived recombinant human BLAME/SLAMF8
Ala23-Asp233
Accession # Q9P0V8

Specificity

Detects human BLAME/SLAMF8 in Western blots. In Western blots, less than 1% cross-reactivity with recombinant human NTB-A/SLAMF6 is observed.

Clonality

Polyclonal

Host

Goat

Isotype

IgG

Scientific Data Images for Human BLAME/SLAMF8 Biotinylated Antibody

Detection of BLAME/SLAMF8 antibody in U937 Human Cell Line antibody by Flow Cytometry.

Detection of BLAME/SLAMF8 in U937 Human Cell Line by Flow Cytometry.

U937 human histiocytic lymphoma cell line was treated for 18 hours with 20 ng/mL Recombinant Human IFN-gamma (Catalog # 285-IF) then stained with Human BLAME/SLAMF8 Biotinylated Antigen Affinity-purified Polyclonal Antibody (Catalog # BAF1907, filled histogram) or isotype control antibody (Catalog # BAF108, open histogram), followed by Streptavidin-Phycoerythrin (Catalog # F0040).

Applications for Human BLAME/SLAMF8 Biotinylated Antibody

Application
Recommended Usage

Flow Cytometry

2.5 µg/106 cells
Sample: U937 human histiocytic lymphoma cell line treated with Recombinant Human IFN-gamma (Catalog # 285-IF)

Western Blot

0.1 µg/mL
Sample: Recombinant Human BLAME/SLAMF8 (Catalog # 1907-BL)

Formulation, Preparation, and Storage

Purification

Antigen Affinity-purified

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS.

Reconstitution Buffer Available:
Size / Price
Qty
Loading...

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: BLAME/SLAMF8

BLAME (B-lymphocyte activator macrophage expressed), also known as SLAM family member 8, is a type I transmembrane protein that belongs to the CD2 subset of immunoglobulin superfamily cell receptors. CD2 family proteins function as adhesion molecules and modulators of immune responses (1, 2). Mature human BLAME consists of a 211 amino acid (aa) ECD that contains two Ig V-like domains, a 21 aa transmembrane segment, and a 31 aa cytoplasmic tail that lacks recognizable signaling motifs (3). Within the ECD, human BLAME shares 19%‑26% aa sequence identity with human 2B4, CD2, CD2F-10, CD48, CD58, CD84, CD229, CRACC, NTB-A, and SLAM. It shares 79% aa sequence identity with the ECD of mouse BLAME. BLAME is expressed on dendritic cells and IFN-gamma stimulated monocytes. Overexpression of BLAME in bone marrow cells leads to an increase in the peritoneal B1b population of B lymphocytes (3).

References

  1. McNerney, M.E. and V. Kumar (2006) Curr. Top. Microbiol. Immunol. 298:91.
  2. Veillette, A. (2006) Nat. Rev. Immunol. 6:56.
  3. Kingsbury, G.A. et al. (2001) J. Immunol. 166:5675.

Long Name

SLAM Family Member 8

Alternate Names

CD353, SBBI42, SLAMF8

Entrez Gene IDs

56833 (Human); 74748 (Mouse); 289237 (Rat); 102122568 (Cynomolgus Monkey)

Gene Symbol

SLAMF8

UniProt

Additional BLAME/SLAMF8 Products

Product Documents for Human BLAME/SLAMF8 Biotinylated Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Human BLAME/SLAMF8 Biotinylated Antibody

For research use only

Loading...
Loading...
Loading...
Loading...
Loading...